InvestorsHub Logo

EOT

Followers 115
Posts 12494
Boards Moderated 0
Alias Born 05/05/2014

EOT

Re: None

Tuesday, 10/15/2019 9:23:30 AM

Tuesday, October 15, 2019 9:23:30 AM

Post# of 113861
You Gotta follow what’s been happening with this company.
And this PR is the key for TAKE OFF!!!!!!!
GET READY$$


For Immediate Release December 12, 2018
SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine’s lead anticancer compound targeted for Pancreatic Cancer. The material which will ultimately be generated by a contract manufacturing organization will be used for animal toxicity studies and clinical trials.

About Crocus Laboratories Inc.
Crocus Laboratories Inc. is a Canadian medicinal chemistry company engaged in the design and synthesis of new chemical entities, including enzyme inhibitors, receptor modulators and compound libraries. The Crocus team has extensive experience in drug discovery and development, particularly in the areas of oncology and infectious diseases. More information about Crocus is available at www.crocuslaboratories.com.

About Sunshine Biopharma’s Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.


FROM NEW WEBSITE.....



“Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for
injection.“


https://www.sunshinebiopharma.org/


I noticed that the statement on the other website was just for pancreatic cancer. This new one includes Breast cancer.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News